Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: A nested case-control study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3482-3490

  Díaz López, Andrés ^a,b   Chacón, Matilde R ^c   Bulló, Mònica ^a,b   Maymó Masip, Elsa ^c   Martínez González, Miguel A ^b,d   Estruch, Ramón ^b,e   Vendrell, Joan ^c   Basora, Josep ^a,b   Díez Espino, Javier ^f   Covas, María Isabel ^b,g   Salas Salvadó, Jordi ^a,b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f Primary Health Care Centre of Tafalla   (Spain)

^g INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CYTOKINE; TWEAK PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INCIDENCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SPAIN;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RISK; TUMOR NECROSIS FACTORS;

EID: 84881513830     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1848     Document Type: Article

References (41)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87: 4-14.
2. Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract. 2010;87:15-19.
3. Sanada H, Yokokawa H, Yoneda M, et al. High body mass index is an important risk factor for the development of type 2 diabetes. Intern Med. 2012;51:1821-1826.
4. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745-E751.
5. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333-1346.
6. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-1801.
7. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94:3171-3182.
8. Chicheportiche Y, Bourdon PR, Xu H, et al.TWEAK, anewsecreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272:32401-32410.
9. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine. 2007;40: 1-16.
10. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:2412-2449.
11. Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J, Chacon MR. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. A case-control study. PLoS One. 2012;7: e43919.
12. Kralisch S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarkersTWEAKare decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 2008;199:440-444.
13. Blanco-Colio LM, Martín-Ventura JL, Muñóz- García B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:916-922.
14. Bover LC, Cardó-Vila M, Kuniyasu A, et al. A previously unrecognized protein-protein interaction betweenTWEAKand CD163: potential biological implications. J Immunol. 2007;178:8183-8194.
15. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 2002;99:378-380.
16. Axelsson J, Møller HJ, Witasp A, et al. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis. 2006;48:916-925.
17. Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf). 2012;77:385-390.
18. Parkner T, Sørensen LP, Nielsen AR, et al. Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia. 2012;55:1856-1862.
19. Møller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem. 2011;57:291-297.
20. Martínez-González MA, Corella D, Salas-Salvadó J, et al. Cohort profile: design and methods of the PREDIMED study. Int J Epidemiol. 2012;41:377-385.
21. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet.NEngl J Med. 2013; 368:1279-1290.
22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(suppl 1):S67-S74.
23. Elosua R, Marrugat J, Molina L, Pons S, Pujol E. Validation of the Minnesota leisure time physical activity questionnaire in Spanish men. TheMARATHOMInvestigators.AmJ Epidemiol. 1994;139: 1197-1209.
24. Schröder H, Fitó M, Estruch R, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. 2011;141:1140-1145.
25. Redon J, Coca A. Guidelines for the diagnosis, evaluation and treatment of hypertension: the point of view of the Spanish Society of Hypertension [in Spanish]. Med Clin (Barc). 2003;121:739-740.
26. Yilmaz MI, Carrero JJ, Ortiz A, et al. SolubleTWEAKplasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1716-1723.
27. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis. 2010;211:322-326.
28. Gonçalves RB, Coletta RD, Silvério KG, et al. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm Res. 2011;60:409-424.
29. Maecker H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005;123: 931-944.
30. Chicheportiche Y, Fossati-Jimack L, Moll S, Ibnou-Zekri N, Izui S. Down-regulated expression ofTWEAKmRNAin acute and chronic inflammatory pathologies. Biochem Biophys Res Commun. 2000; 279:162-165.
31. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
32. Blanco-Colio LM, Martín-Ventura JL, Carrero JJ, et al. Vascular proteomics and the discovery process of clinical biomarkers: the case of TWEAK. Proteomics Clin Appl. 2011;5:281-288.
33. Yilmaz MI, Sonmez A, Ortiz A, et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin JAmSoc Nephrol. 2011;6:785-792.
34. Chacón MR, Richart C, Gómez JM, et al. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine. 2006;33:129-137.
35. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7: 411-425.
36. Vendrell J, Maymó-Masip E, Tinahones F, et al. Tumornecrosis-like weak inducer of apoptosis as a proinflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia. J Clin Endocrinol Metab. 2010;95: 2983-2992.
37. Zhong L, Luo Y, Huang C, Liu L. Effect of NF-αB decoy on insulin resistance of adipocytes from patients with type 2 diabetes mellitus. Diabetes Metab. 2011;37:520-526.
38. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A. siRNAmediated reduction of inhibitor of nuclear factor-αB kinase prevents tumor necrosis factor-α-induced insulin resistance inhumanskeletal muscle. Diabetes. 2008;57:2066-2073.
39. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK+/I+ B/NF-α B axis in obesity-and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003;27(suppl 3):S49-S52.
40. Urbonaviciene G, Martin-Ventura JL, Lindholt JS, et al. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis. 2011;219:892-899.
41. Moreno JA, Muñoz-García B, Martín-Ventura JL, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009;207:103-110.